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Abstract
Vaccinia virus (VACV) encodes multiple proteins inhibiting the NF-kB signalling pathway. One of these, A49, targets the E3
ubiquitin ligase b-TrCP, which is responsible for the ubiquitylation and consequential proteosomal degradation of IkBa and
the release of the NF-kB heterodimer. b-TrCP is a pleiotropic enzyme ubiquitylating multiple cellular substrates, including
the transcriptional activator b-catenin. Here we demonstrate that A49 can activate the Wnt signalling pathway, a critical
pathway that is involved in cell cycle and cell differentiation, and is controlled by b-catenin. The data presented show that
the expression of A49 ectopically or during VACV infection causes accumulation of b-catenin, and that A49 triggering of Wnt
signalling is dependent on binding b-TrCP. This is consistent with A49 blocking the ability of b-TrCP to recognize b-catenin
and IkBa, and possibly other cellular targets. Thus, A49 targeting of b-TrCP affects multiple cellular pathways, including the
NF-kB and Wnt signalling cascades.
Vaccinia virus (VACV), the prototypic member of the
Poxviridae, encodes many proteins that interfere with the
host immune response and thereby generate a cellular
environment that is conducive for viral replication and
spread. Some of these factors act extracellularly and bind
to cytokines and chemokines that are critical for immune
activation and the recruitment of immune cells to the site
of infection [1]. Some others act intracellularly and inhibit
signalling cascades leading to the production of those
cytokines and chemokines, or manipulate cellular path-
ways to facilitate viral protein synthesis, or prevent prema-
ture cell death and hence abortion of the viral replication
cycle [2, 3]. In some cases, a single protein functions in
multiple ways and each function can be ascribed to dis-
crete parts of the viral protein. For instance, protein C16
targets the oxygen-sensing enzyme PHD-2 and induces a
hypoxic response that is metabolically beneficial for the
virus [4, 5], but also inhibits inflammatory signalling
deriving from cytosolic DNA sensing [6]. Protein N1 also
blocks inflammatory signalling downstream of several
receptors, but also prevents cell death [7–10]. This is also
true for protein F1 [11–14], although via a different mech-
anism [15, 16]. This extensive functional redundancy
implies that during infection the concerted action of all
viral proteins ensures a rapid and efficient manipulation
of cellular functions.
Previously, we reported that VACV protein A49 is a viru-
lence factor and inhibits activation of the pro-inflammatory
transcription factor NF-kB [17]. A49 is a small protein that
structurally resembles members of the cellular B-cell
lymphoma (Bcl) 2 family [18], a structural fold that is
shared by a number of VACV proteins [19]. In addition to
the Bcl-2 core, A49 contains an unstructured N-terminal
extension containing a motif resembling that recognized by
the cellular E3 ubiquitin ligase b-TrCP (also known as
FBXW11). b-TrCP is the enzyme responsible for the ubiq-
uitylation and degradation of the inhibitor of kB (IkB)a,
the molecule that retains the NF-kB heterodimer in the cell
cytosol [20]. b-TrCP recognizes the specific sequence Ser–
Gly–Asn–Leu–Ser in IkBa when the two Ser residues are
phosphorylated (Ser 32/36) and conjugates ubiquitin to
upstream lysine residues, leading to the proteasomal degra-
dation of IkBa [21, 22]. The A49 N-terminal extension
mimics the IkBa sequence recognized by b-TrCP, including
the double serine, but not the ubiquitin acceptor lysines
upstream of it. As such, A49 binds b-TrCP without
compromising its own stability, but blocks b-TrCP recogni-
tion of IkBa, and hence NF-kB activation.
The cellular roles for b-TrCP extend beyond NF-kB activa-
tion. The b-TrCP recognition sequence, or degron, is pres-
ent in multiple cellular proteins, and b-TrCP regulates
several cellular processes [23]. Targeting of b-TrCP
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therefore has the potential to affect multiple cellular path-
ways. To determine whether A49 behaves as a broad b-
TrCP inhibitor, or rather displays certain specificity towards
the b-TrCP control of NF-kB, the effects of A49 on another
cellular pathway controlled by b-TrCP, the Wnt pathway,
were explored. The Wnt signalling pathway is important in
cell differentiation and development that becomes active
after the accumulation of cytosolic b-catenin and its subse-
quent translocation to the nucleus [24]. In resting cells, b-
catenin levels remain low due to its constitutive phosphory-
lation by glycogen synthase kinase (GSK) 3b and subse-
quent ubiquitylation by b-TrCP and degradation. Thus b-
TrCP controls b-catenin levels and prevents Wnt signalling
activation, and so targeting of b-TrCP by A49 could
reverse this.
To determine the effect of A49 targeting of b-TrCP on b-
catenin accumulation and Wnt activity, THP-1 monocytic
cells were infected at 10 p.f.u./cell with VACV Western
Reserve lacking A49 (vDA49) and its revertant control
(vA49rev) in which the A49 gene was reinserted in its natu-
ral locus [17]. The levels of b-catenin were monitored over
time by immunoblotting using an antibody against b-cate-
nin (Millipore). The levels of b-actin (Sigma-Aldrich) and
the viral proteins D8 [25] and A49 [17] were also assessed.
Infection with vDA49 did not affect b-catenin levels and
these remained similar to those observed in non-infected
cells (Fig. 1a). Conversely, vA49rev infection induced a pro-
gressive accumulation of b-catenin over time that correlated
with the presence of A49. This experiment was repeated
using quantitative fluorescently labelled secondary antibod-
ies (LI-COR), and b-catenin levels were normalized to those
of viral protein D8. When these ratios were compared
between vDA49 and vA49rev infections,. a statistically sig-
nificant accumulation of b-catenin was observed at 10 and
24 h p.i. (Fig. 1b). HEK293T cells were then transfected with
a plasmid encoding A49 fused to a tandem-affinity purifica-
tion (TAP) tag containing FLAG epitopes [17] or its corre-
sponding empty vector (EV), and 24 h later cells were
treated with medium containing a Wnt3A agonist (a gift
from Mariann Bienz, Laboratory of Molecular Biology) for a
further 6 h. The cells were lysed and divided into cytosolic
and nuclear fractions using a fractionation kit (Pierce), and
the b-catenin levels were measured by immunoblotting.
Cells transfected with A49 had higher levels of b-catenin in
both the cytosolic and nuclear fractions (Fig. 1c). Treatment
with Wnt3A triggered b-catenin accumulation, particularly
in the cytosolic fraction. In the nucleus, b-catenin accumu-
lation was more apparent when both A49 expression and
Wnt3A treatment occurred, which also caused accumula-
tion of nuclear A49. These data demonstrated that A49 is
both necessary and sufficient for b-catenin accumulation.
Translocation of b-catenin to the nucleus promotes its
binding to TCF/LEF transcription factors and dissociation
from transcriptional repressors [24]. To determine whether
A49 was capable of triggering Wnt transcriptional activa-
tion, a reporter plasmid expressing firefly luciferase under
the control of TCF/LEF transcriptional control elements
(Promega) was used. HEK293T cells were seeded and trans-
fected as described [17] with a TCF/LEF-Luc reporter, a
Renilla luciferase (RLuc) control reporter and either TAP-
tagged A49 or its EV control. and then 24 h later the cells
were treated with Wnt3A medium for 6 h or left untreated.
In EV-transfected cells, the Wnt3A treatment induced a
twofold increase in TCF/LEF activity (Fig. 2a). However, in
A49-transfected cells a fourfold increase was achieved, and
this difference was statistically significant. More interest-
ingly, A49 also induced a statistically significant activation
in non-stimulated cells, indicating that the presence of A49
alone was sufficient to increase TCF/LEF reporter activity.
This Wnt signalling activation experiment was repeated
with the co-transfection of a plasmid encoding FLAG-
tagged b-catenin instead of Wnt3A-containing medium. In
these conditions, the presence of A49 did not induce further
TCF/LEF activity (Fig. 2b). This suggested that b-catenin
over-expression and accumulation masked any effect medi-
ated by A49. Finally, the effect of A49 on two cell types
known to behave differently in terms of Wnt signalling –
U2-OS and HCT116 – was investigated. U2-OS cells derive
from a human osteosarcoma and respond to Wnt stimula-
tion, whereas HCT116 cells are a human colon cancer cell
line with constitutive Wnt activation caused by a mutation
in b-catenin that causes its accumulation [26]. Transfection
of A49 induced significant Wnt activation (~30-fold) in U2-
OS cells (Fig. 2c). In HCT116 cells, despite its higher basal
levels of Wnt activity, transfection of A49 did not induce
further TCF/LEF activity when compared to EV-transfected
cells (Fig. 2c). This is consistent with A49 affecting the Wnt
pathway at the level of b-catenin and not downstream of it.
Taken together, these data demonstrate that A49 expression
triggers b-catenin accumulation and Wnt signalling
activation.
To confirm that the A49 effect on Wnt activation derives
from its ability to target b-TrCP, A49 mutants in which the
N-terminal extension that contains the b-TrCP recognition
motif Ser–Gly–Asn–Leu–Glu–Ser (SGNLES) had been
modified were used (Fig. 3a). Firstly, these mutants were
assessed for their ability to bind b-TrCP in LUMIER assays
[27]. b-TrCP was cloned as a fusion to RLuc and over-
expressed in HEK293T cells in conjunction with each TAP-
tagged A49 allele. The VACV protein C6 was used as a
control [28]. FLAG-tagged Vpu (a gift from Paul Lehner,
Cambridge Institute for Medical Research) was also
included, because this human immunodeficiency virus
(HIV) protein interacts with b-TrCP [29]. Cell lysates were
prepared 24 h post transfection and subjected to immuno-
precipitation with FLAG agarose (Sigma-Aldrich) as
described [8], utilizing the FLAG epitope present in all
TAP-tagged proteins and Vpu. Rluc activity was measured
in both the inputs and the final immunoprecipitated eluates,
and a ratio between these activities was calculated for each
condition and plotted as a binding fold over the C6 control.
As expected, wild-type A49 (A49.WT) associated with b-
TrCP and this was quantitated as a ~fivefold increase over
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control (Fig. 3b). HIV Vpu bound b-TrCP to a higher
extent, in agreement with its higher expression level. Con-
versely, a mutant of A49 lacking the first 12 residues
(A49.D12), and hence the entire b-TrCP degron, showed no
binding, despite higher expression levels than A49.WT.
Replacement of the two critical Ser residues for Ala (S7/
12A) abrogated binding to b-TrCP, although a minimal but
reproducible association was detected and showed statistical
significance. In contrast to A49.S/A, substitution of both Ser
for Glu (S7/12E) restored and even enhanced binding com-
pared to A49.WT. This indicates that in A49 Glu efficiently
mimics phosphorylated Ser, in agreement with previous
observations [17]. These mutants were then tested for their
ability to activate Wnt signalling (Fig. 3c). As in Fig. 2(a),
A49.WT induced a ~twofold increase in reporter activity,
and this was enhanced up to ~fourfold after treatment with
Wnt3A agonist. Conversely, A49.D12 did not activate Wnt
signalling. This was also the case for A49.S/A. However, this
mutant did trigger statistically significant reporter activity
after activation with Wnt3A, possibly reflecting its marginal
ability to bind b-TrCP (shown in Fig. 3b). Remarkably,
A49.S/E doubled the extent of Wnt activation compared to
A49.WT, and this was barely increased by Wnt3A treat-
ment, suggesting that HEK293T cells were unable to
respond any further to Wnt signalling stimulation. The lev-
els of A49 from these lysates were assessed by immunoblot-
ting. Whilst the levels of both A49.D12 and A49.S/A
remained similar, those of A49.WT and A49.S/E were lower
when Wnt3A treatment was applied. This observation
might be ascribed to the enhanced stabilization or transloca-
tion of A49 in the nucleus upon Wnt3A activation, a phe-
nomenon already reported in Fig. 1c that affects the A49
alleles engaging b-TrCP for reasons that remain unclear. In
summary, these data demonstrate that the ability of A49 to
target b-TrCP correlates with its ability to activate Wnt sig-
nalling, and that this resides in the b-TrCP degron motif
located at the N terminus.
A49 is one of many VACV proteins that inhibit NF-kB sig-
nalling and contribute to virulence. The NF-kB pathway is a
critical signalling pathway in inflammation and contributes
to type I interferon (IFN) production. Hallmarks of NF-kB
activation include the phosphorylation of IkBa by the
upstream kinase IkB kinase (IKK)-b; the subsequent degra-
dation of IkBa; and the translocation of the NF-kB
Fig. 1. A49 expression leads to b-catenin accumulation. (a) THP-1
cells were infected with VACV lacking A49 (vDA49) or its revertant
control (vA49.Rev) at 10 p.f.u./cell and lysed at different hours (h) post-
infection with RIPA buffer. Whole-cell lysates were subjected to
immunoblotting as indicated. (b) Levels of b-catenin and viral protein
D8 were determined at 10 and 24 h post-infection (p.i.) with vDA49
(white bars) or vA49.Rev (black bars) from three different experiments,
and the corresponding ratios were plotted as the mean ±SD. Statistical
analysis was performed using a Student’s t-test. *, P-value<0.05; ***,
P-value<0.001. (c) Levels of b-catenin and A49 (FLAG) were deter-
mined by immunoblotting in the cytosolic (Cyto) and nuclear (Nuc)
fractions of HEK293T cells previously transfected for 24 h with TAP-
tagged A49 or the corresponding empty vector (EV), and treated sub-
sequently for 6 h with Wnt3A-containing medium (black bars) or left
untreated (white bars). One of two independent experiments with simi-
lar results is shown. AU, arbitrary units.
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heterodimer p65/p50 into the nucleus. Most NF-kB inhibi-
tors encoded by VACV target cellular components required
for the extracellular signal to transduce and induce IkBa
phosphorylation [2], although there is evidence that VACV
inhibits NF-kB activation downstream of p65 translocation
[30]. In contrast, and somewhat counterintuitively for an
NF-kB inhibitor, protein A49 does not prevent IkBa phos-
phorylation. It does, however, block NF-kB activation by
preventing the degradation of phosphorylated IkBa, a phe-
nomenon explained by its ability to bind and inhibit b-
TrCP [17]. b-TrCP is a pleiotropic E3 ubiquitin ligase
targeting substrates involved in multiple cellular processes.
Consequently, VACV targeting of b-TrCP can dysregulate
other cellular pathways in addition to inhibiting NF-kB acti-
vation. The data presented here indicate that the VACV
protein A49 activates Wnt signalling, and this is dependent
on its ability to target b-TrCP. This indicates that VACV
targeting of b-TrCP is not specific to NF-kB regulation, and
that A49 has not evolved mechanisms to distinguish
between b-TrCP molecules involved in NF-kB or Wnt acti-
vation, and may consequently act as a broad b-TrCP inhibi-
tor. Another well-described viral interactor of b-TrCP is the
HIV protein Vpu. Vpu also binds b-TrCP via a degron
sequence that is similar to that found in IkBa or b-catenin
[29]. Thus, it shares striking mechanistic similarities with
A49. Consistent with the pan-b-TrCP inhibitor model, Vpu
also triggered Wnt activation in our assays (data not
shown). This suggests that viral proteins harbouring the b-
TrCP degron sequence can block the degradation of b-
TrCP substrates and interfere with their biological
pathways.
A49 targeting of b-TrCP inhibits NF-kB activation, induces
Wnt signalling and has the potential to alter other b-TrCP-
controlled cellular processes. This raises the following ques-
tions: (1) what is the A49’s principal function? and (2) is all
of the A49-induced activity beneficial for the virus? It is for-
mally very difficult to tease apart the different functions of
A49 if they all lie in the b-TrCP degron motif and rely on
the interaction with b-TrCP. It is important to note that the
interaction between A49 and b-TrCP depends on the phos-
phorylation of the Ser residues in the degron. We do not
currently know which kinase(s) phosphorylate(s) A49, but
it is conceivable that this is performed by the same kinases
that usually phosphorylate b-TrCP substrates, e.g. IKK-b,
which phosphorylates IkBa in the NF-kB pathway, or GSK-
3b, which phosphorylates b-catenin in the Wnt pathway
[24]. Phosphorylation by IKK-b or GSK-3b would allow
A49 to interact with b-TrCP in response to specific cellular
challenges, NF-kB or Wnt signalling agonists in this case.
Therefore, the post-translational phosphorylation of A49
may be a regulatory mechanism determining the A49 func-
tion and activity. Of note and in contrast to most VACV
immunomodulators, which are expressed early during
infection, A49 is expressed throughout the entire viral cycle,
perhaps fulfilling different roles at different stages.
Whether Wnt activation or any other phenotype caused by
A49 targeting of b-TrCP is beneficial or detrimental to
VACV is currently unknown. Our data indicate that VACV
infection leads to b-catenin accumulation, but an increase
in Wnt reporter activity when cells were infected with WR
at different m.o.i.s was not seen (data not shown). This may
indicate that VACV interferes with Wnt signalling
Fig. 2. A49 triggers Wnt signalling activity. (a) HEK293T cells were transfected for 24 h with a Wnt-specific luciferase reporter, a con-
trol reporter, and TAP-tagged A49 or empty vector (EV). The cells were then stimulated for a further 6 h with Wnt3A-containing
medium (black bars) or left unstimulated (white bars). Luciferase activity was calculated and plotted as the mean fold increase ±SD
over the unstimulated EV condition. (b) HEK293T cells were transfected as above, as well as with 50 ng per well of a plasmid encoding
FLAG-tagged b-catenin (black bars) or EV (white bars). Luciferase activity was calculated 24 h post-transfection as above. (c) U2-OS or
HCT116 cells were transfected with TAP-tagged A49 (black bars) or EV (white bars). Luciferase activity was calculated 24 h post-trans-
fection as above. One of at least three independent experiments performed in triplicate is shown in each panel. Statistical analysis
was performed using a Student’s t-test. *, P-value<0.05; **, P-value<0.01.
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downstream of b-catenin through the concerted action of
one or more viral proteins. It is also possible that the b-cate-
nin transcriptional activation is masked in our experimental
setting by the gross changes induced by VACV infection.
Multiple viruses affect Wnt signalling (reviewed in [31]).
HHV-5 and HHV-1 cause cellular redistribution of b-
Fig. 3. The N-terminal extension of A49 determines its ability to target b-TrCP and to activate Wnt signalling. (a) Schematic of A49 tar-
geting of the E3 ubiquitin ligase complex containing b-TrCP and mutagenesis of the N-terminal extension of A49 in which residues 1–
12 were deleted (A49.D12), or Ser 7 and 12 residues were changed to Ala (A49.S/A) or Glu (A49.S/E). (b) LUMIER assay showing the
ability of each A49 protein to associate with b-TrCP fused to renilla luciferase (RLuc-b-TrCP). HEK293T cells were co-transfected in
triplicate with RLuc-b-TrCP and each of the TAP-tagged A49 alleles, C6 or Vpu as indicated, and 24 h later luciferase activity was mea-
sured in the cell lysates and also in the eluates deriving from FLAG immunoprecipitation. The ratio lysate/eluate for each condition
was calculated and plotted as the mean binding fold ±SD over the C6 control condition. Immunoblotting for FLAG or a–tubulin from the
same lysates is shown below, as indicated. One of two experiments performed in triplicate is shown. (c) Luciferase assay showing the
ability of each A49 protein to activate Wnt signalling. HEK293T cells were transfected for 24 h with a Wnt-specific luciferase reporter,
a control reporter and each of the TAP-tagged A49 alleles or EV, as indicated. The cells were then stimulated for a further 6 h with
Wnt3A-containing medium (black bars) or left unstimulated (white bars). Luciferase activity was calculated and plotted as the mean
fold increase ±SD over the unstimulated EV condition. Immunoblotting for FLAG or a–tubulin from the same lysates is shown below.
Replicate wells were pooled and centrifuged at 14 000 g for 30 mins, and post-nuclear supernatants were subjected to SDS-PAGE as
indicated. One of at least three independent experiments performed in triplicate is shown. Statistical analysis was performed using a
Student’s t-test. *, P-value<0.05; **, P-value<0.01; ***, P-value<0.001; , not significant.
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catenin [32–34]. Cancer-causing viruses, such as the human
herpesvirus (HHV) 4, HHV-8, human papillomavirus, or
human polyomavirus JC, upregulate b-catenin and Wnt
gene expression. Interestingly, HHV-4 late membrane pro-
tein (LMP) 1, which interacts with b-TrCP via an IkB-like
degron [35], induces nuclear accumulation of b-catenin
[36], suggesting that LMP-1 and A49 activate Wnt signal-
ling by similar mechanisms. VACV and poxviruses in gen-
eral are cytolytic and do not cause cancer. Manipulation of
b-catenin and Wnt signalling may, however, provide opti-
mal cell cycle conditions for virus replication. Interestingly,
a role for the Wnt pathway in modulating the host inflam-
matory and anti-viral response was reported recently [37–
44]. Although the outcome of this modulation may differ
between experimental settings, in some cases Wnt activity
supports viral replication and dampens innate immune sig-
nalling [42–44]. This model would complement the role of
A49 in down-regulating NF-kB activation and the IFN
response. Future studies will establish the contribution of b-
catenin accumulation and Wnt signalling to this down-
regulation.
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